Global Pneumococcal Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pneumococcal Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccineconjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
Pneumococcal Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumococcal Vaccine market is projected to reach US$ 7780.4 million in 2034, increasing from US$ 7200.2 million in 2022, with the CAGR of 1.1% during the period of 2024 to 2034. Demand from Child and Adult are the major drivers for the industry.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, End User and Regions Listed in the Report
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumococcal Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumococcal Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumococcal Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product End User, Volume and Revenue analysis of Each End User in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumococcal Vaccine introduction, etc. Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pneumococcal Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
There are two types of Pneumococcal Vaccineconjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
Pneumococcal Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumococcal Vaccine market is projected to reach US$ 7780.4 million in 2034, increasing from US$ 7200.2 million in 2022, with the CAGR of 1.1% during the period of 2024 to 2034. Demand from Child and Adult are the major drivers for the industry.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, End User and Regions Listed in the Report
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumococcal Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumococcal Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumococcal Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product End User, Volume and Revenue analysis of Each End User in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumococcal Vaccine introduction, etc. Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pneumococcal Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices